Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography
1 other identifier
observational
178
1 country
1
Brief Summary
Framingham risk score is well known screening tool that detect cardiovascular (CV) risk. But it is not suitable for CV risk in mild risk group. So 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a new imaging technique for detecting vascular inflammation within atherosclerotic plaques and hsCRP is also arising detection tool of CV risk. The investigators are examining this association in normal and impaired glucose tolerance patients groups.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2009
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2010
CompletedFirst Submitted
Initial submission to the registry
June 8, 2010
CompletedFirst Posted
Study publicly available on registry
June 9, 2010
CompletedJune 9, 2010
February 1, 2010
5 months
June 8, 2010
June 8, 2010
Conditions
Keywords
Study Arms (2)
normal
normal group has no diabetes.
IGT
IGT group has impaired fasting glucose or impaired glucose tolerance.
Eligibility Criteria
The subjects underwent routine health checkups at Korea University Guro Hospital. Patients with DM or gestational diabetes were not included.
You may qualify if:
- healthy subjects
You may not qualify if:
- a history of cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization)
- active inflammatory disease, recent active infection
- stage 2 hypertension (resting blood pressure, ≥ 160/100 mmHg)
- diabetes mellitus
- systemic disorders such as severe hepatic, renal, and hematologic diseases
- taking drugs known to interfere with vascular inflammation measured by FDG-PET.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Korea university guro hospital
Seoul, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
June 8, 2010
First Posted
June 9, 2010
Study Start
September 1, 2009
Primary Completion
February 1, 2010
Study Completion
February 1, 2010
Last Updated
June 9, 2010
Record last verified: 2010-02